|D053120||Respiratory Aspiration NIH||0.28|
|D012120||Respiration Disorders NIH||0.23|
|D012140||Respiratory Tract Diseases NIH||0.20|
There is one clinical trial.
As a serosurveillance measure asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for COVID-19 IgG antibodies. Of the tested employees who were positive for COVID-19 IgG antibodies the study aimed to find the percentage of cases who retained their COVID-19 IgG antibodies 45-65 days after initially testing positive.
Description: Percentage of cases retaining SARS-CoV-2 IgG antibodies at 45-65 daysMeasure: Percentage of cases retaining SARS-CoV-2 IgG antibodies at 45-65 days Time: 45-65 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports